Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

Melanotan II vs PT-141: Melanocortin Receptor Selectivity Explained

Two conceptual cyclic peptide schematics share a six-residue ring and external norleucine residue, with contrasting terminal groups.

Melanotan II and PT-141 (bremelanotide) are α-MSH analogues with a shared cyclic heptapeptide scaffold. Their documented structural difference is at the C-terminus: MT-II is Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Lys)-NH2, while PT-141 has the same core ending in a free acid, -OH, instead of the terminal amide.[1] MT-II is described as a non-selective agonist at MC1R, MC3R, MC4R and MC5R.[2] PT-141 binds MC1R, MC3R and MC4R, with higher affinity for MC4R than MC3R in the review’s account.[1] That preference does not make PT-141 an exclusively MC4R-active molecule, nor establish which peptide is more selective in a head-to-head comparison.

The useful distinction is between receptor binding, receptor activation and a measured human outcome. A binding constant, a cAMP response in an engineered cell line and a clinical questionnaire result do not answer the same question.

What Melanocortin Receptor Selectivity Is Measured Against

Conceptual split panel showing a peptide at a membrane receptor and a separate intracellular signalling response.

Five melanocortin receptors are known, MC1R through MC5R. They are seven-transmembrane G protein-coupled receptors of the rhodopsin family, differing in tissue distribution and their responses to endogenous melanocortin ligands.[3] Both peptides are analogues of α-MSH, but belonging to this ligand family does not mean that every receptor responds identically to them.

A selectivity claim needs a comparison between receptor subtypes, not simply evidence that a compound activates one receptor. The compiled binding table lists MT-II Ki values of 1.3 nM for MC3R and 1.1 nM for MC4R, alongside α-MSH values of 30 nM and 5 nM, respectively. The PT-141 row records the Ki columns as N/A.[1] These are receptor-binding measurements, not dose values or human-response thresholds.

Functional testing asks a different question. In HEK-293 cells expressing MC4R, PT-141 increases cAMP production, supporting its classification as an agonist at that receptor.[1] This establishes activity in that cell system; it does not supply the missing PT-141 binding constants or compare its activity across every melanocortin subtype.

The MT-II constants are literature values compiled in a review, not a matched comparison with PT-141. They should not be used to calculate a cross-compound selectivity ranking. Likewise, PT-141’s MC4R cAMP response cannot substitute for a head-to-head binding experiment. Binding and functional results can complement one another, but neither fills a missing measurement in the other category.

The Structural Difference: One Cyclized Core, Two C-Termini

MT-II was developed from the linear peptide Melanotan-I as an artificial-tanning candidate. Cyclization was introduced to prevent degradation and allow truncation at the N- and C-termini.[1] Its systematic name identifies a cyclic (2–7) peptide containing norleucine and D-phenylalanine, ending in lysinamide.[2] The seven-residue peptide and the ring itself are therefore not synonymous: the cyclic segment runs from aspartate to lysine.

Three structural features clarify the comparison:

  • The lactam ring. In bremelanotide, an amide bond joins the β-carboxyl group of aspartate to the ε-amino group of the C-terminal lysine.[4] Both published sequences show the same cyclic Asp–His–D-Phe–Arg–Trp–Lys segment.[1]
  • The D-amino acid. Both sequences contain D-phenylalanine.[1] Bremelanotide’s cyclic structure and incorporation of D-amino acids are described as contributing to stability, but that description is not a measured stability comparison with MT-II.[4]
  • The terminal group. MT-II ends in -NH2; bremelanotide ends in -OH. One review calls PT-141 a “deaminated derivative,” but the structural difference documented by its sequence table sits at the C-terminus.[1] Bremelanotide is also described explicitly as an active metabolite of MT-II lacking the C-terminal amide group.[5]

MT-II is partly metabolized into bremelanotide.[2] That relationship connects the molecules, but does not make a study of one a study of the other. The terminal-group difference also does not, by itself, demonstrate a change in tissue distribution or quantify a change in receptor preference. Those conclusions require measurements beyond the sequence comparison.

Receptor Profiles: Relative Preference, Not Selectivity

MT-II’s reported MC3R and MC4R constants are numerically close, while its described agonist profile includes MC1R and MC5R as well.[1][2] For PT-141, strong binding to MC1R, MC3R and MC4R coexists with a reported MC4R-over-MC3R preference.[1] A clinical review likewise describes bremelanotide as non-selective, with activity thought to act mainly through MC3R and MC4R.[6]

“Preference” and “exclusive activity” are different claims. The MC4R-over-MC3R description compares two receptors within PT-141’s broader profile; it does not remove MC1R from that profile. Nor does it show that PT-141 has a larger selectivity margin than MT-II, because the table supplies no matching PT-141 constants.

MC2R is not a reliable differentiator here. The clinical review includes MC2R in its receptor list, whereas the bremelanotide entry explicitly excludes it.[6][5] This disagreement leaves MC2R activity unresolved in the supplied evidence; it cannot support a firm five-receptor ranking.

Tissue Distribution Explains the Phenotype Split

Conceptual pigment-related cell panel beside a brain silhouette with a hypothalamic neuron inset.

MC1R and MC4R connect the shared receptor profile to different biological contexts. MT-II-associated melanogenesis is attributed to MC1R activation.[2] MC4R-expressing neurons occur across several regions of the central nervous system, including the hypothalamic medial preoptic area.[4] The distinction is between receptor locations and functions, not proof that either peptide acts in only one tissue.

In rats, pro-erectile effects have been attributed to hypothalamic MC3R and/or MC4R. The same review states that the exact receptor responsible for the human erectile response is not established.[1] Animal receptor attribution therefore needs to remain separate from human findings.

Bremelanotide’s reported hyperpigmentation also matters to this comparison: central research endpoints do not imply absence of pigment-related activity. Melanocortin agonism may increase melanin expression, and hyperpigmentation is among the reported adverse effects.[6] Neither that observation nor the CNS distribution of MC4R provides a quantitative comparison of the two peptides’ tissue exposure.

What the Human Studies Measured

An early PT-141 phase 1 study summarized in the review involved 24 healthy men. It measured serum concentrations and RigiScan-recorded rigidity, reporting a longer rigidity duration than placebo.[1] The sample was small, the participants were healthy volunteers, and rigidity was a physiological endpoint rather than a receptor-level measurement. The summary does not establish whether MC3R, MC4R or another contribution accounted for the observation.

The later RECONNECT programme concerned bremelanotide in premenopausal women with hypoactive sexual desire disorder. Participants were randomized 1:1 to bremelanotide or placebo over 24 weeks. Primary endpoints were changes in FSFI-D and FSDS-DAO, covering desire and associated distress. The review reports significant increases in desire scores and reductions in distress, with nausea, flushing and headache more frequent than placebo.[6]

These designs address different populations and endpoints. Rigidity measurements in healthy men cannot be treated as equivalent to desire and distress questionnaires in women with a defined disorder. The supplied RECONNECT summary does not give its participant count, so it cannot support a numerical sample-size comparison. Both summaries concern PT-141/bremelanotide; neither is a direct human comparison against MT-II.

A placebo-controlled clinical result also is not a receptor-selectivity result. The trial endpoints do not separate the contributions of individual melanocortin receptors. They describe the studied product and population, not efficacy or an indication for MT-II or for research materials.

Pharmacokinetics Belongs to the Tested Product

The early PT-141 study summary reports serum concentrations peaking at approximately 30 minutes in the highest studied group and a serum half-life of about 120 minutes.[1] These describe exposure in that study, not receptor preference and not a matched pharmacokinetic comparison with MT-II. No corresponding human MT-II dataset is included in the supplied evidence.

Bremelanotide’s development also included an earlier formulation discontinued after blood-pressure signals and a later reformulated product.[5] Transient blood-pressure increases remain among the adverse effects summarized in the clinical review.[6] Formulation history and tolerability findings should stay attached to the product studied, rather than becoming assumptions about another peptide sharing its scaffold.

Why One Compound’s Data Cannot Be Transferred to the Other

The comparison has three distinct limits. Structurally, a shared ring does not erase the different C-terminal groups or the documented metabolism of MT-II into bremelanotide. Pharmacologically, the available binding table does not provide paired constants for both molecules, and the PT-141 cAMP finding concerns one receptor-expressing cell system. Clinically, the human studies summarized above examine PT-141/bremelanotide rather than a head-to-head comparison with MT-II.

The supported conclusion is therefore specific: these are related, broadly active melanocortin agonists, not a demonstrated MC1R-only peptide versus an MC4R-only peptide. PT-141’s reported relative preference for MC4R over MC3R is compatible with activity at other receptors. Establishing which compound is more selective would require comparable measurements for both, rather than transferring a binding value, a signalling response or a human endpoint from one molecule to the other.

Related research: What Is Melanotan II: Cyclic Alpha-MSH Analog; What Is PT-141: Bremelanotide and Melanocortin Research; Melanotan II.

Research use only. Materials supplied by SaiyanMed are for laboratory research. This article summarises published literature on two peptides; it is not medical advice and does not describe or endorse any human or veterinary use, dose, route or preparation.

References

  1. Melanocortin Receptors, Melanotropic Peptides and Penile Erection (Curr Top Med Chem, 2007)
  2. Melanotan II — Wikipedia
  3. Melanocortin receptor — Wikipedia
  4. Exploring FDA-Approved Frontiers: Natural and Engineered Peptide Analogues
  5. Bremelanotide — Wikipedia
  6. Bremelanotide for Treatment of Female Hypoactive Sexual Desire (review)